Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode.

Yatham LN, Fountoulakis KN, Rahman Z, Ammerman D, Fyans P, Marler SV, Baker RA, Carlson BX.

J Affect Disord. 2013 May;147(1-3):365-72. doi: 10.1016/j.jad.2012.11.042. Epub 2013 Jan 3.

PMID:
23290791
2.
3.

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.

Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN.

Curr Med Res Opin. 2010 Jun;26(6):1485-96. doi: 10.1185/03007991003779380.

PMID:
20429835
4.

A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.

Yatham LN.

J Affect Disord. 2011 Jan;128 Suppl 1:S21-8. doi: 10.1016/S0165-0327(11)70005-2. Review.

PMID:
21220077
5.

A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R; Aripiprazole Study Group.

J Clin Psychiatry. 2006 Apr;67(4):626-37.

PMID:
16669728
6.

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study.

Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, Owen R, Nameche L.

Am J Psychiatry. 2008 Oct;165(10):1316-25. doi: 10.1176/appi.ajp.2008.07101560. Epub 2008 Apr 1.

PMID:
18381903
7.

Aripiprazole alone or in combination for acute mania.

Brown R, Taylor MJ, Geddes J.

Cochrane Database Syst Rev. 2013 Dec 17;(12):CD005000. doi: 10.1002/14651858.CD005000.pub2. Review.

PMID:
24346956
8.

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.

Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH; CN138-135 Study Group.

J Affect Disord. 2009 Jan;112(1-3):36-49. doi: 10.1016/j.jad.2008.05.014. Epub 2008 Oct 2.

PMID:
18835043
9.

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R; Aripiprazole Study Group.

J Clin Psychiatry. 2007 Oct;68(10):1480-91.

PMID:
17960961
10.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N.

Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. Review.

11.

A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.

El-Mallakh RS, Marcus R, Baudelet C, McQuade R, Carson WH, Owen R.

J Affect Disord. 2012 Feb;136(3):258-66. doi: 10.1016/j.jad.2011.11.043. Epub 2011 Dec 30.

PMID:
22209190
12.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
13.

Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.

Kemp DE, De Hert M, Rahman Z, Fyans P, Eudicone JM, Marler SV, Baker RA, Carlson BX.

J Affect Disord. 2013 May 15;148(1):84-91. doi: 10.1016/j.jad.2012.11.054. Epub 2012 Dec 20.

PMID:
23261129
14.

Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.

Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B.

J Affect Disord. 2008 Apr;107(1-3):145-54. Epub 2007 Sep 27.

PMID:
17904226
15.

Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.

Woo YS, Bahk WM, Chung MY, Kim DH, Yoon BH, Lee JH, Ahn YM, Chung SK, Kim JG, Lee KH, Paik KC.

Hum Psychopharmacol. 2011 Dec;26(8):543-53. doi: 10.1002/hup.1240. Epub 2011 Dec 2.

PMID:
22134973
16.

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J.

Cochrane Database Syst Rev. 2013 Oct 17;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. Review.

PMID:
24132760
17.

Olanzapine in long-term treatment for bipolar disorder.

Cipriani A, Rendell JM, Geddes J.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004367. doi: 10.1002/14651858.CD004367.pub2. Review.

PMID:
19160237
18.

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2002 Jan;59(1):62-9.

PMID:
11779284
19.

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.

Bowden CL, Karayal ON, Schwartz JH, Gundapaneni BK, O'Gorman C.

J Affect Disord. 2013 Jan 10;144(1-2):171-5. doi: 10.1016/j.jad.2012.04.024. Epub 2012 Sep 21.

PMID:
22999893
20.

Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.

Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M.

J Clin Psychiatry. 2006 Jan;67(1):95-101.

PMID:
16426094
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk